In acute infective exacerbation of chronic bronchitis or chronic obstructive pulmonary disease (COPD), adding erdosteine to standard treatment significantly modified the outcome by improving the ...

In COPD, muscular atrophy is a significant risk factor for death and may prolong patients’ hospital length of stay.

The effect of erdosteine on mucus rheological properties was evaluated in patients with exacerbation of COPD. [24] Patients receiving erdosteine had statistically significant reduction in sputum ...